A clinical trial listing dated July 20, 2026 describes a study of mazdutide titled "Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide." The trial is registered under identifier NCT07713992. Its current status is listed as not yet recruiting. The phase field for this study is listed as not applicable. The listing indicates the study population includes patients with type 2 diabetes mellitus and moderate to severe nonalcoholic fatty liver disease who have prior treatment history with semaglutide. No efficacy or safety results have been posted for this trial. No enrollment numbers, timelines beyond the registration date, or outcome data are included in the available record. Mazdutide remains classified as an unapproved compound under research investigation. This update reflects only the registration and current recruitment status of the study as listed. Readers interested in background on mazdutide can consult the compound overview for further context.
Mazdutide Trial NCT07713992 Registered, Not Yet Recruiting
See the full mazdutide overview
Source: https://clinicaltrials.gov/study/NCT07713992